311 related articles for article (PubMed ID: 34580062)
21. The deubiquitinase USP5 promotes cholangiocarcinoma progression by stabilizing YBX1.
Ning F; Du L; Li J; Wu T; Zhou J; Chen Z; Hu X; Zhang Y; Luan X; Xin H; Yuan C; Zhang X
Life Sci; 2024 Jul; 348():122674. PubMed ID: 38692507
[TBL] [Abstract][Full Text] [Related]
22. Enhanced expression of ten-eleven translocation 1 reverses gemcitabine resistance in cholangiocarcinoma accompanied by a reduction in P-glycoprotein expression.
Wang C; Ye H; Zhang L; Cheng Y; Xu S; Zhang P; Zhang Z; Bai J; Meng F; Zhong L; Shi G; Li H
Cancer Med; 2019 Mar; 8(3):990-1003. PubMed ID: 30784212
[TBL] [Abstract][Full Text] [Related]
23. MiR-124 induces autophagy-related cell death in cholangiocarcinoma cells through direct targeting of the EZH2-STAT3 signaling axis.
Ma J; Weng L; Wang Z; Jia Y; Liu B; Wu S; Cao Y; Sun X; Yin X; Shang M; Mao A
Exp Cell Res; 2018 May; 366(2):103-113. PubMed ID: 29530475
[TBL] [Abstract][Full Text] [Related]
24. MicroRNA-92a promotes epithelial-mesenchymal transition through activation of PTEN/PI3K/AKT signaling pathway in non-small cell lung cancer metastasis.
Lu C; Shan Z; Hong J; Yang L
Int J Oncol; 2017 Jul; 51(1):235-244. PubMed ID: 28534966
[TBL] [Abstract][Full Text] [Related]
25. MicroRNA-146b promotes PI3K/AKT pathway hyperactivation and thyroid cancer progression by targeting PTEN.
Ramírez-Moya J; Wert-Lamas L; Santisteban P
Oncogene; 2018 Jun; 37(25):3369-3383. PubMed ID: 29353884
[TBL] [Abstract][Full Text] [Related]
26. CircRNA hsa_circ_0002577 accelerates endometrial cancer progression through activating IGF1R/PI3K/Akt pathway.
Wang Y; Yin L; Sun X
J Exp Clin Cancer Res; 2020 Aug; 39(1):169. PubMed ID: 32847606
[TBL] [Abstract][Full Text] [Related]
27. miR-181b-5p Promotes the Progression of Cholangiocarcinoma by Targeting PARK2 via PTEN/PI3K/AKT Signaling Pathway.
Jiang ZL; Zhang FX; Zhan HL; Yang HJ; Zhang SY; Liu ZH; Jiang Y; Lv LZ; Ke RS
Biochem Genet; 2022 Feb; 60(1):223-240. PubMed ID: 34169384
[TBL] [Abstract][Full Text] [Related]
28. The Upregulation of OCT4 in Acidic Extracellular pH is Associated with Gemcitabine Resistance in Cholangiocarcinoma Cell Lines.
Choodetwattana P; Proungvitaya S; Jearanaikoon P; Limpaiboon T
Asian Pac J Cancer Prev; 2019 Sep; 20(9):2745-2748. PubMed ID: 31554372
[TBL] [Abstract][Full Text] [Related]
29. Atorvastatin Augments Gemcitabine-Mediated Anti-Cancer Effects by Inhibiting Yes-Associated Protein in Human Cholangiocarcinoma Cells.
Kitagawa K; Moriya K; Kaji K; Saikawa S; Sato S; Nishimura N; Namisaki T; Akahane T; Mitoro A; Yoshiji H
Int J Mol Sci; 2020 Oct; 21(20):. PubMed ID: 33066548
[TBL] [Abstract][Full Text] [Related]
30. High mobility group A1 enhances tumorigenicity of human cholangiocarcinoma and confers resistance to therapy.
Quintavalle C; Burmeister K; Piscuoglio S; Quagliata L; Karamitopoulou E; Sepe R; Fusco A; Terracciano LM; Andersen JB; Pallante P; Matter MS
Mol Carcinog; 2017 Sep; 56(9):2146-2157. PubMed ID: 28467612
[TBL] [Abstract][Full Text] [Related]
31. STYK1 promotes epithelial-mesenchymal transition and tumor metastasis in human hepatocellular carcinoma through MEK/ERK and PI3K/AKT signaling.
Wang Z; Qu L; Deng B; Sun X; Wu S; Liao J; Fan J; Peng Z
Sci Rep; 2016 Sep; 6():33205. PubMed ID: 27628214
[TBL] [Abstract][Full Text] [Related]
32. Combined targeting of AKT and mTOR using MK-2206 and RAD001 is synergistic in the treatment of cholangiocarcinoma.
Ewald F; Grabinski N; Grottke A; Windhorst S; Nörz D; Carstensen L; Staufer K; Hofmann BT; Diehl F; David K; Schumacher U; Nashan B; Jücker M
Int J Cancer; 2013 Nov; 133(9):2065-76. PubMed ID: 23588885
[TBL] [Abstract][Full Text] [Related]
33. Micro-RNA-130a-3p Regulates Gemcitabine Resistance via PPARG in Cholangiocarcinoma.
Asukai K; Kawamoto K; Eguchi H; Konno M; Asai A; Iwagami Y; Yamada D; Asaoka T; Noda T; Wada H; Gotoh K; Nishida N; Satoh T; Doki Y; Mori M; Ishii H
Ann Surg Oncol; 2017 Aug; 24(8):2344-2352. PubMed ID: 28560603
[TBL] [Abstract][Full Text] [Related]
34. MORC2 promotes cell growth and metastasis in human cholangiocarcinoma and is negatively regulated by miR-186-5p.
Liao G; Liu X; Wu D; Duan F; Xie X; Wen S; Li Y; Li S
Aging (Albany NY); 2019 Jun; 11(11):3639-3649. PubMed ID: 31180332
[TBL] [Abstract][Full Text] [Related]
35. Oncogenic activity of retinoic acid receptor γ is exhibited through activation of the Akt/NF-κB and Wnt/β-catenin pathways in cholangiocarcinoma.
Huang GL; Luo Q; Rui G; Zhang W; Zhang QY; Chen QX; Shen DY
Mol Cell Biol; 2013 Sep; 33(17):3416-25. PubMed ID: 23798555
[TBL] [Abstract][Full Text] [Related]
36. Neurotensin promotes cholangiocarcinoma metastasis via the EGFR/AKT pathway.
Su ZJ; Liu XY; Zhang JH; Ke SY; Fei HJ
Gene; 2019 Mar; 687():143-150. PubMed ID: 30359740
[TBL] [Abstract][Full Text] [Related]
37. YAP is a critical oncogene in human cholangiocarcinoma.
Pei T; Li Y; Wang J; Wang H; Liang Y; Shi H; Sun B; Yin D; Sun J; Song R; Pan S; Sun Y; Jiang H; Zheng T; Liu L
Oncotarget; 2015 Jul; 6(19):17206-20. PubMed ID: 26015398
[TBL] [Abstract][Full Text] [Related]
38. Activation of the PI3K-AKT signaling pathway by SPARC contributes to the malignant phenotype of cholangiocarcinoma cells.
Deng S; Zhang L; Li J; Jin Y; Wang J
Tissue Cell; 2022 Jun; 76():101756. PubMed ID: 35217388
[TBL] [Abstract][Full Text] [Related]
39. GSG2 knockdown suppresses cholangiocarcinoma progression by regulating cell proliferation, apoptosis and migration.
Zhou J; Nie W; Yuan J; Zhang Z; Mi L; Wang C; Huang R
Oncol Rep; 2021 Jun; 45(6):. PubMed ID: 33846801
[TBL] [Abstract][Full Text] [Related]
40. TCF21 inhibits tumor-associated angiogenesis and suppresses the growth of cholangiocarcinoma by targeting PI3K/Akt and ERK signaling.
Duan HX; Li BW; Zhuang X; Wang LT; Cao Q; Tan LH; Qu GF; Xiao S
Am J Physiol Gastrointest Liver Physiol; 2019 Jun; 316(6):G763-G773. PubMed ID: 30920845
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
